ClinicalTrials.gg
CompletedNCT07215286Updated Sep 9, 2026

Comparative Study on SNAG From Different Positions Low Back Pain Treatment

An interventional study of Loaded-SNAG and Unloaded-SNAG in Chronic Low Back Pain (CLBP), sponsored by University of Hail. Completed at 1 site in Saudi Arabia. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University of Hail · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Low Back Pain with a site in Saudi Arabia — 5 open to participants now, 5 under way, none of them phase 3. Low Back Pain · Saudi Arabia.

Enrollment
13th of 24
59 · median 60
Started
2025
with 3 others
No phase
24 of 27
5 open now
Registered
23rd of 27
by date
Lead sponsor
3 of 27
University of Hail

Among the 27 studies in Low Back Pain with a site in Saudi Arabia, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2025, is one of 24 with no phase, and was the 23rd registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 27 studies in Low Back Pain with a site in Saudi Arabia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Saudi Arabia have not opened yet or have stopped. Only those recruiting at a site in Saudi Arabia →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Low Back Pain with a site in Saudi Arabia, or all of them as a file.
02

Study summary

Objectives: To compare the effects of lumbar sustained natural apophyseal glides (SNAGs) applied in loaded versus unloaded positions on pain, disability, and function in individuals with chronic nonspecific LBP.

Methods: A sample of 59 participants was assigned to receive six sessions of standard intervention, with lumbar SNAGs applied in either a loaded (sitting) or an unloaded (quadruped) position. This study was conducted between November 2025 and May 2026. Outcomes measured pre- and post-intervention included pain intensity (VAS), lumbar flexion range of motion (BROM device), and functional disability (Oswestry Disability Index).

Read the detailed description

Low back pain (LBP) is a global health problem with an estimated lifetime prevalence of up to 80% in adults [1]. It is one of the leading causes of disability worldwide and places a substantial burden on health care systems and economies. Although most cases are nonspecific, patients often experience significant pain, restricted mobility, and impaired function, which negatively affect their quality of life [2].

The global burden of low back pain remains substantial, particularly among middle-aged adults (45-59 years), with a disability-adjusted life years rate of 747.92 per 100,000 population in 2021. Notably, high body mass index was the only risk factor showing a significant increasing trend (estimated annual percentage change = 1.08) over the past three decades [3]. This epidemiological context underscores the clinical importance of our comparison, as loaded SNAGs may be particularly relevant for overweight/obese patients who experience greater gravitational loading on the lumbar spine during daily activities Management strategies typically involve a combination of exercise, patient education, and manual therapy [3]. Among manual therapy approaches, the Mulligan Concept - specifically, Sustained Natural Apophyseal Glides (SNAGs) - has gained attention due to its reported immediate effects on pain reduction and mobility.

SNAGs are a form of Mulligan concept mobilization-with-movement in which the therapist applies a sustained accessory glide to a spinal segment. At the same time, the patient actively performs the symptomatic movement. Evidence suggests SNAGs can improve pain, lumbar range of motion (ROM), and functional status in patients diagnosed with nonspecific LBP [4-6].

A central principle of SNAGs is their application in functional, weight-bearing positions that reflect real-life movement demands. However, physiotherapists sometimes apply SNAGs in unloaded positions (e.g., prone or quadruped) in both clinical settings and research situations. 9,10 Biomechanical research demonstrates that spinal loading alters facet joint kinematics and tissue stresses, suggesting that the clinical effect of SNAGs may depend on whether they are applied in a loaded or unloaded position [7, 8]. Despite this, no randomised controlled trials (RCTs) have directly compared these two SNAG modes.

This study aims to address this gap by comparing the clinical effectiveness of lumbar SNAGs applied in loaded versus unloaded positions on pain, ROM, and function in patients with chronic nonspecific LBP.

03

Conditions studied

  • Chronic Low Back Pain (CLBP)

Browse trials for

Keywords

  • Manual therapy
  • Mobilization with Movement
  • Spine
  • Mulligan
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic non specific low back pain for 6 weeks or more
  • Who scored between three and six on a visual analogue scale (VAS)
  • Restriction of the movement was only in flexion ROM

Exclusion criteria

Exclusion Criteria:

  • Pregnancy,
  • Obese,
  • Infectious conditions of the spine,
  • disorders,
  • Any to physiotherapy and manual therapy
  • Any patient received physical therapy sessions last 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Active comparator
    Loaded-SNAG

    SNAGs from standing position

    Procedure: Loaded-SNAG · Procedure: Unloaded-SNAG

  • Active comparator
    Unloaded-SNAG

    SNAG from quadruped position

    Procedure: Loaded-SNAG · Procedure: Unloaded-SNAG

Interventions

  • ProcedureLoaded-SNAG

    patients will receive SNAGs from standing (Loaded-SNAG), step-stance, or functional position that provokes symptoms. A specialized Mulligan belt was used around the patient's waist and the therapist's hips. The mobilizing force was applied parallel to the facet joint plane (cephalic direction) and over the spinous processes of the respective symptomatic spinal levels. The therapist's hand's ulnar aspect was used over the spinous process of the superior vertebra of the involved segment for flexion glide. The therapist applies accessory glide to targeted zygapophyseal level while the patient actively performs symptomatic movement (e.g., forward flexion), performing repetitions with the therapist maintaining the glide.

  • ProcedureUnloaded-SNAG

    patients will receive unloaded SNAG from quadruped position to reduce the axial loading. The therapist applies the equivalent accessory glide at the symptomatic spinal level while the patient performs the symptomatic movement (modified to be non-weight-bearing).

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Visual analogue scale (VAS), which is a 10-cm line, 0 denotes no pain and 10 the most intense agony.

    Time frame: 1 week

  2. Lumbar flexion ROM

    The BROM is an electronic goniometer that will be used to evaluate the range of motion for trunk flexion

    Time frame: 1 week

Secondary outcomes

  1. Functional disability

    The functional level was assessed using a validated Arabic version of the Oswestry Disability Index (ODI). A total score will be calculated, the percentage of disability (score obtained divided by 50 and multiplied by 100) ranged from 0% (no disability) to 100% (complete disability).

    Time frame: 1 week

07

Study locations

1 site
  • University Medical Clinics
    Ha'il, 0000, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No — The project is supervised by university of Hail and all the data should be authorized through it

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in May 2026, 7 months.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 10, 2025
StartActual
Oct 15, 2025
Primary completionActual
May 30, 2026
CompletionActual
May 30, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215286
Lead sponsor
University of Hail
Responsible party
Ehab Mohamed Kamel Ahmed (Assistant Professor, University of Hail) — Principal investigator
First posted
Oct 10, 2025
Start date
Oct 15, 2025
Primary completion
May 30, 2026
Completion
May 30, 2026
Last update
Sep 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion